Last updated: September 6, 2026
Fosnetupitant chloride hydrochloride and palonosetron hydrochloride are the active ingredients in the intravenous formulation of Akynzeo, an antiemetic combination for chemotherapy-induced nausea and vomiting. The product combines an NK1 receptor antagonist prodrug, fosnetupitant, with the 5-HT3 receptor antagonist palonosetron.
Akynzeo has a defensible commercial position because it addresses both acute and delayed chemotherapy-induced nausea and vomiting in a single administration. Its growth is constrained by generic palonosetron, inexpensive aprepitant-based regimens, hospital formulary purchasing, and the limited size of the intravenous antiemetic market.
The commercial outlook is stable rather than high growth. Revenue depends on oncology treatment volumes, conversion from multi-drug antiemetic protocols, hospital contracting, and the durability of patent and regulatory protection.
What is fosnetupitant and palonosetron used for?
Akynzeo injection is used in adults to prevent acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic cancer chemotherapy.
The intravenous dose contains:
| Component |
Role |
Dose in Akynzeo injection |
| Fosnetupitant chloride hydrochloride |
Prodrug of netupitant; NK1 receptor antagonist |
235 mg |
| Palonosetron hydrochloride |
5-HT3 receptor antagonist |
0.25 mg |
Fosnetupitant is converted in vivo to netupitant. The combination is designed to provide coverage across the early and delayed phases of chemotherapy-induced nausea and vomiting. The product is administered before chemotherapy, reducing the need for separate oral NK1 and 5-HT3 agents.
The oral version of Akynzeo contains netupitant and palonosetron directly. The intravenous formulation was developed to address patients who cannot reliably take oral medication and to simplify administration in infusion centers.
What is the FDA regulatory status of Akynzeo injection?
The FDA approved the intravenous formulation of Akynzeo in September 2018. The product is approved under New Drug Application 210493 for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy [1].
The oral formulation was approved earlier, in 2014, under the Akynzeo brand. The FDA-approved intravenous product is distinct because it uses fosnetupitant, a water-soluble prodrug of netupitant, rather than netupitant itself.
FDA regulatory milestones
| Milestone |
Date |
Commercial relevance |
| Oral netupitant/palonosetron approval |
2014 |
Established the Akynzeo franchise |
| European approval of Akynzeo |
2015 |
Expanded the product across major European oncology markets |
| U.S. IV fosnetupitant/palonosetron approval |
September 2018 |
Added an infusion-center formulation |
| Launch of IV product in major markets |
2018 onward |
Expanded use in patients unable to take oral therapy |
Akynzeo is not a biologic. Biosimilar substitution is therefore not relevant. The main competitive threat is generic substitution or therapeutic substitution involving aprepitant, fosaprepitant, palonosetron and other antiemetic combinations.
What patents protect fosnetupitant and palonosetron?
Protection for Akynzeo is built around several patent categories:
- The netupitant active ingredient and related chemical compounds.
- Fosnetupitant prodrug chemistry.
- Injectable formulations and aqueous stability.
- Combination treatment with palonosetron.
- Methods for preventing chemotherapy-induced nausea and vomiting.
- Dosing and administration protocols covering acute and delayed emesis.
The intravenous product is commercially important from a patent perspective because fosnetupitant solves a formulation problem. Netupitant is poorly suited to direct intravenous administration, while fosnetupitant is designed to provide a suitable injectable form.
How strong is the patent estate?
The estate is stronger for the intravenous formulation than for the basic antiemetic concept. The combination of an NK1 antagonist and a 5-HT3 antagonist is clinically established and may face broad prior-art arguments. The more defensible claims are likely to focus on:
- Specific fosnetupitant compounds and salts.
- Formulation stability.
- Conversion of fosnetupitant to netupitant.
- Specified concentrations and dosage forms.
- The particular combination with palonosetron.
- Manufacturing processes for sterile injectable product.
Formulation and process patents can delay direct substitution even when composition-of-matter protection has expired. Their practical value depends on claim scope, Orange Book listing, enforceability and whether a generic applicant can design around the claims.
The U.S. Orange Book should be reviewed for the current patent list associated with NDA 210493 and the oral Akynzeo NDA. The relevant filing structure may include separate patents for the oral and intravenous products. Patent expiration dates can also differ by jurisdiction because of patent-term adjustment, supplementary protection certificates and pediatric extensions.
When does Akynzeo lose exclusivity?
Akynzeo does not have one universal loss-of-exclusivity date. Exclusivity differs by:
- Oral versus intravenous formulation.
- United States versus Europe and other markets.
- Active-ingredient patents versus formulation patents.
- Regulatory exclusivity versus patent protection.
- The timing of generic filing and litigation.
FDA regulatory exclusivity for the original oral product has expired. The current commercial barrier is therefore primarily patent-based rather than orphan-drug or new-chemical-entity exclusivity.
The injectable product received five-year new chemical entity exclusivity only if the FDA treated the relevant active moiety and approval structure as qualifying for that protection. That period has expired. Current U.S. entry risk depends on the Orange Book patents and the outcome of any Paragraph IV litigation.
In Europe, supplementary protection certificates and national patent rights may extend effective protection beyond the underlying patent term. European entry is therefore country-specific.
Generic entry scenarios
| Scenario |
Timing effect |
Likely commercial result |
| No Paragraph IV challenge |
Entry after patent expiry |
Gradual erosion, initially limited by manufacturing capacity |
| Paragraph IV challenge defeated |
Generic entry delayed |
Brand retains hospital contracts and premium pricing |
| Paragraph IV settlement |
Entry at negotiated date |
Predictable but potentially material revenue decline |
| Formulation patent design-around |
Earlier entry possible |
Generic competes with IV product while avoiding selected claims |
| Oral-only generic entry |
Limited impact on IV demand |
Substitution concentrated in ambulatory and oral-treatment settings |
Which companies are challenging Akynzeo?
Publicly visible competitive pressure comes primarily from established generic antiemetic manufacturers rather than from a direct biosimilar developer. Companies active in the relevant market include Teva, Sandoz, Fresenius Kabi, Dr. Reddy’s Laboratories, Hikma, Cipla and other regional suppliers.
The main competitive products are:
- Generic palonosetron injection.
- Fosaprepitant injection.
- Aprepitant capsules and oral suspension.
- Generic ondansetron and granisetron.
- Netupitant/palonosetron products where approved.
- Multi-drug antiemetic protocols using corticosteroids and other agents.
A direct generic version of fosnetupitant/palonosetron would face greater technical complexity than a palonosetron generic. The product requires sterile injectable manufacturing, control of prodrug conversion, impurity management and formulation stability. Those requirements raise development cost and reduce the number of credible entrants.
No broad public record establishes a large-scale, settled Paragraph IV challenge to the IV product comparable to the challenges seen for major oncology drugs. The practical risk is more likely to emerge through individual ANDA filings, patent litigation and formulation workarounds.
What is the Orange Book status of fosnetupitant/palonosetron?
Akynzeo injection is an FDA-approved prescription drug subject to Orange Book patent listing. The Orange Book is the controlling public source for determining:
- Listed U.S. patents.
- Patent expiration dates.
- Pediatric exclusivity.
- Approved dosage forms.
- Reference-listed-drug status.
- Generic filing opportunities.
The Orange Book does not capture every commercially relevant barrier. It does not fully describe manufacturing know-how, trade secrets, non-listed process patents, supplier qualification, sterile fill-finish capacity or regulatory execution risk.
For investors and generic developers, the critical distinction is between patents listed against the intravenous NDA and patents listed only against oral Akynzeo. Oral and injectable products should not be treated as having identical exclusivity profiles.
How does Akynzeo compare with competing antiemetic regimens?
| Product or regimen |
Administration |
Competitive advantage |
Main limitation |
| Akynzeo IV |
Single pre-chemotherapy infusion |
NK1 and 5-HT3 coverage in one product |
Higher acquisition cost than generic components |
| Oral Akynzeo |
Single oral dose |
Convenient outpatient administration |
Not suitable for all patients |
| Fosaprepitant plus palonosetron |
Two components, often IV |
Broad hospital familiarity |
More administration steps |
| Aprepitant plus generic 5-HT3 agent |
Oral or mixed |
Low cost and broad generic availability |
Multiple drugs and schedules |
| Palonosetron alone |
IV |
Low cost, established use |
Inadequate NK1 blockade for some regimens |
| Ondansetron-based regimens |
Oral or IV |
Very low price |
Less differentiated delayed-emesis coverage |
Akynzeo competes on convenience and regimen simplification rather than price. That positioning is most effective in highly emetogenic chemotherapy, where prevention of delayed nausea has clinical and operational value.
What is the financial trajectory of Akynzeo?
Helsinn owns the Akynzeo franchise and has commercial relationships in selected markets, including licensing and distribution arrangements. Public financial reporting generally does not provide a separate audited revenue line for fosnetupitant injection. Reported Akynzeo figures may combine oral and intravenous products, geographic sales, licensing income and product revenue depending on the reporting period.
The financial trajectory has the following characteristics:
| Driver |
Direction |
Impact |
| Oncology treatment volume |
Stable to growing |
Supports baseline demand |
| IV formulation adoption |
Positive |
Increases franchise breadth |
| Generic palonosetron pricing |
Negative |
Compresses regimen economics |
| Hospital purchasing pressure |
Negative |
Limits price increases |
| Product differentiation |
Positive |
Supports retention in high-risk chemotherapy |
| Generic fosaprepitant competition |
Negative |
Creates therapeutic substitution |
| International expansion |
Positive |
Reduces reliance on the U.S. market |
| Patent expiry |
Negative |
Creates step-down risk after entry |
Akynzeo should be modeled as a mature specialty pharmaceutical rather than a high-growth launch product. Revenue can expand through market share gains, intravenous conversion and international penetration, but the product is exposed to price erosion in a heavily genericized therapeutic category.
A reasonable commercial model separates the franchise into three revenue pools:
- U.S. intravenous revenue, which has the highest patent and contracting sensitivity.
- U.S. and European oral revenue, which is more exposed to generic and therapeutic substitution.
- International revenue, where patent expiry and reimbursement rules vary by country.
Revenue exposure to generic entry
The likely erosion pattern depends on whether entry is oral, injectable or both.
- Oral generic entry would pressure capsule pricing and could shift physicians toward low-cost multi-drug regimens.
- A competing IV fosnetupitant/palonosetron product would create direct price pressure and threaten hospital contracts.
- A generic fosaprepitant product would produce indirect pressure by offering an alternative NK1 component.
- Multiple injectable entrants would accelerate price erosion and reduce the value of formulation differentiation.
For a direct IV generic, first-year erosion could be limited by sterile manufacturing capacity, hospital conversion cycles and formulary review. Once multiple suppliers qualify, erosion would likely accelerate.
What manufacturing and IP barriers affect generic launch?
The principal manufacturing barriers are technical rather than clinical:
- Sterile injectable production.
- Control of particulate matter and endotoxins.
- Stability of the fosnetupitant prodrug.
- Reproducible conversion to netupitant.
- Control of degradation products.
- Compatibility with infusion equipment.
- Validated aseptic fill-finish processes.
- Reliable supply of pharmaceutical-grade active ingredient.
The formulation also creates regulatory complexity. An applicant must demonstrate pharmaceutical equivalence and bioequivalence or an appropriate alternative for an injectable product. Small differences in excipients, impurities or degradation profiles can delay approval.
These barriers make a direct IV generic less straightforward than a palonosetron injection. They do not eliminate entry risk, but they can reduce the number of credible first entrants.
What licensing deals affect Akynzeo?
Helsinn has historically used licensing and regional commercialization partnerships for its oncology and supportive-care products. Commercial rights may differ by market, with local partners responsible for registration, promotion, distribution or reimbursement access.
Licensing affects financial analysis in three ways:
- Net sales may be divided between product revenue and royalty income.
- A regional partner may control launch timing and pricing.
- Contract terms can reduce the originator’s direct selling expense while lowering reported revenue retention.
A complete valuation should therefore distinguish Helsinn’s consolidated product sales from its economic share of market sales. Public disclosures do not consistently provide product-level partner economics for every territory.
What litigation and settlement risks should investors monitor?
The key legal events are:
- ANDA filing with a Paragraph IV certification.
- Notice to the patent holder.
- Filing of a patent-infringement action within the statutory period.
- Potential 30-month stay of FDA approval.
- Claim construction and validity decisions.
- Settlement with an agreed generic-entry date.
- Final approval and commercial launch.
The most material litigation issues would involve obviousness, written description, enablement, claim construction and whether the generic product practices formulation or method claims.
Settlement terms may include a licensed entry date, launch contingencies, manufacturing restrictions, supply arrangements or authorized-generic provisions. A settlement date is usually more important for valuation than the nominal patent expiration date.
Key Takeaways
- Fosnetupitant chloride hydrochloride and palonosetron hydrochloride are the active ingredients in IV Akynzeo.
- The product is FDA-approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting.
- Its commercial advantage is single-administration NK1 and 5-HT3 coverage, not low cost.
- The oral and intravenous products have different regulatory and patent profiles.
- Direct IV generic entry is more technically difficult than generic palonosetron entry.
- The main financial risks are hospital price pressure, therapeutic substitution and patent-driven generic entry.
- Public financial reporting does not generally isolate revenue from the fosnetupitant injection alone.
- The product is best modeled as a mature specialty franchise with stable demand and asymmetric downside after direct generic entry.
- Orange Book patents, Paragraph IV filings and settlement dates are the primary U.S. exclusivity indicators.
- Biosimilar risk is not relevant because Akynzeo is a small-molecule drug.
FAQs
Is fosnetupitant the same drug as netupitant?
No. Fosnetupitant is a prodrug that is converted in the body to netupitant. It was developed to provide a suitable intravenous form of the NK1 antagonist.
Is Akynzeo injection interchangeable with fosaprepitant?
No. Both provide NK1 receptor antagonism, but they are different active ingredients, formulations and approved products. Substitution depends on institutional protocols and applicable regulatory rules.
Does palonosetron patent expiry eliminate Akynzeo’s protection?
No. Generic palonosetron may create therapeutic and pricing pressure without establishing legal permission to copy the fosnetupitant/palonosetron combination.
Can a generic manufacturer avoid Akynzeo patents?
Potentially. A manufacturer may pursue a formulation or process design-around, omit patented indications through a skinny label where legally available, or challenge listed patents through a Paragraph IV certification.
What is the largest commercial threat to Akynzeo?
The largest threat is a combination of direct IV competition and therapeutic substitution from lower-cost fosaprepitant or aprepitant regimens. Either event could reduce pricing power even before complete patent-driven displacement.
References
- U.S. Food and Drug Administration. (2018). Akynzeo injection prescribing information. FDA.
- U.S. Food and Drug Administration. (2014). Akynzeo capsules prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- Helsinn Healthcare SA. (2023). Annual report and financial results. Helsinn.
- European Medicines Agency. (2015). Akynzeo: EPAR product information. EMA.
- National Cancer Institute. (2024). Nausea and vomiting related to cancer treatment. National Institutes of Health.
